Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the completion of the sale, the chief operating officer now owns 218,083 shares of the company’s stock, valued at $6,112,866.49. The trade was a 4.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.

Akero Therapeutics Price Performance

Shares of AKRO stock opened at $27.64 on Tuesday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -7.37 and a beta of -0.19. The business’s fifty day moving average is $30.49 and its 200 day moving average is $27.95. Akero Therapeutics, Inc. has a twelve month low of $15.32 and a twelve month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares during the last quarter. Eastern Bank purchased a new stake in shares of Akero Therapeutics in the third quarter worth $100,000. Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics during the third quarter valued at $205,000. Victory Capital Management Inc. purchased a new position in shares of Akero Therapeutics in the 3rd quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Akero Therapeutics in the 3rd quarter worth about $265,000.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup started coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.